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ABSTRACT
Objective We aimed to identify the country- level 
determinants of the severity of the first wave of the 
COVID-19 pandemic.
Design Ecological study of publicly available data. Countries 
reporting >25 COVID-19 related deaths until 8 June 2020 
were included. The outcome was log mean mortality rate 
from COVID-19, an estimate of the country- level daily 
increase in reported deaths during the ascending phase of 
the epidemic curve. Potential determinants assessed were 
most recently published demographic parameters (population 
and population density, percentage population living in urban 
areas, population >65 years, average body mass index and 
smoking prevalence); economic parameters (gross domestic 
product per capita); environmental parameters (pollution 
levels and mean temperature (January–May); comorbidities 
(prevalence of diabetes, hypertension and cancer); health 
system parameters (WHO Health Index and hospital beds 
per 10 000 population); international arrivals; the stringency 
index, as a measure of country- level response to COVID-19; 
BCG vaccination coverage; UV radiation exposure; and 
testing capacity. Multivariable linear regression was used to 
analyse the data.
Primary outcome Country- level mean mortality rate: the 
mean slope of the COVID-19 mortality curve during its 
ascending phase.
Participants Thirty- seven countries were included: 
Algeria, Argentina, Austria, Belgium, Brazil, Canada, Chile, 
Colombia, the Dominican Republic, Ecuador, Egypt, Finland, 
France, Germany, Hungary, India, Indonesia, Ireland, Italy, 
Japan, Mexico, the Netherlands, Peru, the Philippines, 
Poland, Portugal, Romania, the Russian Federation, Saudi 
Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, 
Ukraine, the UK and the USA.
Results Of all country- level determinants included in the 
multivariable model, total number of international arrivals 
(beta 0.033 (95% CI 0.012 to 0.054)) and BCG vaccination 
coverage (−0.018 (95% CI −0.034 to –0.002)), were 
significantly associated with the natural logarithm of the 
mean death rate.
Conclusions International travel was directly associated 
with the mortality slope and thus potentially the spread 
of COVID-19. Very early restrictions on international travel 
should be considered to control COVID-19 outbreaks and 
prevent related deaths.
INTRODUCTION
The atypical pneumonia caused by 
SARS- CoV-2 has spread rapidly. As of the 
8 June 2020, there have been over 400 857 
deaths related to COVID-19 infection world-
wide.1 The estimated overall case fatality rate 
is ~7%, with country- level estimates ranging 
between 0.5% and 14%.2 Nevertheless, there 
is wide variation in the reported country- 
specific death rates which may be attributed 
to variation in testing rates, under- reporting 
or real differences in environmental, sociode-
mographic and health system parameters.
Country- level determinants of the 
pandemic severity are largely unknown. The 
only previous ecological study to date assessing 
country- level determinants of the severity of 
the COVID-19 pandemic including data on 
65 countries3 has found that the cumulative 
number of infected patients in each country 
was directly associated with the case fatality 
Strengths and limitations of this study
 ► A relevant outcome variable quantifying country- 
level increases in the COVID-19 death rate was 
derived, which is largely independent of different 
testing policies adopted by each country.
 ► Our multivariable regression models accounted 
for public health and economic measures, which 
were adopted by each country in response to the 
COVID-19 pandemic by adjusting for the stringency 
index.
 ► The main limitation of the study stems from the 
ecological study design, which does not allow for 
conclusions to be drawn for individual patients with 
COVID-19.
 ► Only countries that had reported at least 25 daily 
deaths over the analysed period were included, 
which reduced our sample and consequently the 
power.
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rate, while testing intensity was inversely associated with 
case fatality rate. This study found no association between 
health expenditure and case fatality rate. However, other 
important country- level determinants were not evalu-
ated, and thus, their relationship with pandemic severity 
remains unknown.
Several risk factors for COVID-19 related mortality 
have been proposed, including older population,4 higher 
population comorbid burden,5 smoking,6 obesity,7 pollu-
tion levels8 and healthcare system performance.9 Further-
more, countries outside China most severely hit by the 
first wave of the pandemic were those with a high income, 
high gross domestic product (GDP) per capita and well- 
established healthcare systems, such as Italy, Spain, 
France, the UK and the USA.10 In contrast, lower- income 
and middle- income countries reported much lower 
COVID-19 incidence and mortality rates.10 While these 
differences may be attributable to case under- reporting 
and infrequent testing in these countries, other factors 
may also be involved.
In this study, we aimed to assess the country- level deter-
minants of the severity of the first wave of the COVID-19 
pandemic based on currently available evidence using 
publicly available data and an ecological study design.
METHODS
Patient and public involvement
There was no patient or public involvement in designing 
the study given the urgent nature of the COVID-19 
pandemic and the usage of publicly available data.
Study design
An ecological study design was used. The outcome was 
the steepness of the ascending curve of country- specific 
daily reports of COVID-19 related deaths between 31 
December 2019 and 8 June 2020. The following determi-
nants were assessed: demographic determinants (popula-
tion and population density, percentage population living 
in urban areas, proportion of population aged 65 years 
and over, average body mass index (BMI) and smoking 
prevalence); economic determinants (GDP per capita); 
environmental determinants (pollution levels and mean 
temperature (January–May) (2010–2016)); prevalent 
comorbidities (diabetes, hypertension and cancer); 
health systems determinants (WHO Health Index and 
hospital beds per 10 000 population); international 
arrivals (as a proxy measure of the globalisation status 
of each country); the stringency index (SI) (as measure 
of country level response to the pandemic)11; exposure 
to UV radiation (as a proxy for sunlight exposure); BCG 
vaccination coverage; and testing capacity.
Ethics committee approval
Given the study design and the use of publicly available 
data, no ethical approval was considered necessary.
Selection criteria
Countries reporting at least 25 daily deaths up to 8 June 
2020 with available data for all chosen determinants were 
included. A total of 37 countries from four continents 
were included in the analysis: Africa (Algeria, Egypt and 
South Africa), America (Argentina, Brazil, Canada, Chile, 
Colombia, the Dominican Republic, Ecuador, Mexico, 
Peru and the USA), Asia (India, Indonesia, Japan, the Phil-
ippines, Saudi Arabia and Turkey) and Europe (Austria, 
Belgium, Finland, France, Germany, Hungary, Ireland, 
Italy, the Netherlands, Poland, Portugal, Romania, the 
Russian Federation, Spain, Sweden, Switzerland, Ukraine 
and the UK). China was not included in the analysis due 
to potential inaccuracies in the number of daily reported 
deaths that may have occurred subsequent to 1290 deaths, 
which were retrospectively reported on 17 April.12
Data sources
Country- level parameters were obtained from freely 
accessible data sources. The daily reported number of 
COVID-19 cases and deaths between 31 December 2019 
and 8 June 2020 as well as the 2018 population data 
were extracted from the European Centre for Disease 
Control.13
The data regarding the median population age and 
population density were extracted from the United 
Nations World Population Prospects14 and United Nations 
Statistics Division, respectively.15 The data regarding the 
percentage of the population living in urban areas were 
extracted from the World Urbanisation Prospects, issued 
by the United Nations Population Division.16 Tempera-
ture data were extracted from the Climate Change Knowl-
edge Portal from the World Bank Group.17 Prevalent 
diabetes, GDP, international arrivals in 2018 and current 
health expenditure data were extracted from the World 
Development Indicators database, provided by the World 
Bank Group.18 Data regarding prevalent cancers, propor-
tion of population aged 65 years and over and the total 
number of COVID-19 tests performed were extracted 
from the Our World in Data and the Sustainable Devel-
opment Goals tracker,19 20 an open- access publication 
tracking global progress to the United Nations Sustain-
able Development Goals for global development, 
adopted in September 2015. Prevalent hypertension, 
BMI, cigarette smoking, ambient air pollution, ultraviolet 
(UV) radiation and BCG vaccination data were obtained 
from the Global Health Observatory data repository of 
the WHO.21 The WHO health index was extracted from 
the WHO Global Partnership for Education paper series 
published in 2000.22 Country- level total hospital beds per 
10 000 population data were extracted from the World 
Bank Dataset ‘World Bank Indicators of Interest to the 
COVID-19 Outbreak’.23 Daily SI measurements between 
31 January 2019 and 8 June 2020 were extracted from the 
Oxford COVID-19 Government Response Tacker.11
Definition of outcome and determinants
Outcome
While previous ecological studies of other epidemics 
have used case or death counts as outcome,24 this may 
be prone to bias due to variations in country- level testing 
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strategies,25 variations in population movement controls 
and differences in secondary attack rates within commu-
nity cohorts.26 The mean mortality rate was thus chosen as 
outcome instead, since it is independent of these param-
eters and may thus represent a more reliable indicator 
of the country- level severity of the COVID-19 pandemic.
Mean mortality rate was defined as the mean slope of 
the mortality curve (figure 1), measured from the first 
day when more than two COVID-19 deaths were reported 
until either the mortality curve reached a peak value or 
8 June 2020, whichever occurred first. The peak of each 
mortality curve was defined as the first point at which 
the first derivate of the COVID-19 mortality curve as a 
function of the pandemic timeline became zero. Before 
slope calculation, the mortality curve in each country 
was smoothed using a locally weighted (Lowess) regres-
sion using a bandwidth of 0.4. In order to ensure a good 
fit of the Lowess regression line, only countries having 
reported at least 25 daily deaths until the 8 June 2020 
were included. The mean mortality rate thus represents 
an estimate of the country- level daily increase in reported 
deaths during the ascending phase of the epidemic curve.
Determinants
Data on population density were extracted as the country- 
level population per square kilometre in 2019.27 Data on 
ambient air pollution were extracted as the country- level 
mean concentration of fine particulate matter (PM2.5) 
measured in 2016.28 Temperature data were extracted as 
the mean temperature recorded in each country between 
January and May using temperature data recorded 
between 2010 and 2016.17 Data on international arrivals 
were extracted as the total number of country- level inter-
national arrivals in 2018.29
Data on prevalent diabetes were extracted as the 
percentage of the population aged 20–79 years in 
2019.18 Data on prevalent cancers were extracted as the 
age- standardised cancer prevalence among both sexes 
in 2017, expressed as percentages.30 Data on prevalent 
hypertension were extracted as the age- standardised 
percentage of the population over 18 years of age with 
systolic blood pressure ≥140 mm Hg or diastolic blood 
pressure ≥90 mm Hg in 2015.31 Data on BMI were 
extracted as the age- standardised mean body mass index 
trend estimates for both sexes among adults (≥18 years) 
in 2016.32 Data on daily cigarette smoking were extracted 
as the age- standardised smoking rate across both sexes 
among adults (≥18 years) in 2013.33 While the definition 
of ‘daily cigarette smoking’ varies across surveys, it habit-
ually refers to current smoking of cigarettes at least once 
a day.33
Data on GDP were extracted as GDP per capita by 
purchasing power parity (PPP) in current international 
dollars in 2018.34 The percentage of population living 
in urban areas was defined as the percentage of de facto 
population living in areas classified as urban according 
to the criteria used by each area or country.16 The WHO 
health index is a composite index that aims to evaluate 
a given country’s healthcare system performance rela-
tive to the maximum it could achieve given its level of 
resources and non- healthcare system determinants. It was 
calculated in the year 2000. The index uses five weighted 
parameters: overall or average disability- adjusted life 
expectancy (25%), distribution or equality of disability- 
adjusted life expectancy (25%), overall or average health-
care system responsiveness (including speed of provision 
and quality of amenities; 12.5%), distribution or equality 
of healthcare system responsiveness (12.5%) and health-
care expenditure (25%). Data on hospital beds per 10 000 
population were defined by the World Bank as including 
‘inpatient beds available in public, private, general, and 
specialized hospitals and rehabilitation centres’. The 
published data for the included countries were between 
2000 and 2017. In most cases, beds for both acute and 
chronic care were included.23 The SI is an overall indi-
cator of public health measures adopted by each country 
in response to the COVID-19 pandemic and includes 
containment and closure indicators (school closures, 
workplace closures, cancelling public events, restric-
tions on gatherings, public transport closures, stay- at- 
home requirements, restrictions on internal movements 
and international travel controls), economic response 
indicators (income support, debt/contract relief, fiscal 
measures and international support) as well as health 
system indicators (public information campaigns, testing 
policy, contact tracing, emergency investment in health-
care and investment in vaccines).11 The mean daily SI was 
calculated for each country between 31 December 2019 
and until either the mortality curve reached a peak value 
or 8 June 2020, whichever occurred first.
Country- level exposure to UV radiation was quanti-
fied as the population- weighted average daily ambient 
Figure 1 Graphical representation of the smoothed* number 
of daily deaths of each country (before reaching mortality 
peak, if applicable) as a function of the number of days 
passed since the first day when an excess of three deaths 
were reported. Countries with higher mean mortality rates 
are depicted in blue, while those with lower mean mortality 
rates are depicted in red. *Smoothed using a local regression 
(Lowess) function with a bandwidth of 0.4.
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ultraviolet radiation level measured in J/m2 for the years 
1997–2003.35 BCG vaccination coverage was quantified 
as the average percentage of 1- year- old children having 
received the BCG vaccine between 1980 and 2019 in 
each country. Testing capacity was quantified as the 
total number of COVID-19 tests per 1000 population 
performed until 8 June 2020.
Country- level intensive care unit (ICU) capacity was 
not included in the analyses, given the absence of a data-
base centralising this information and the resulting poor 
reporting. Furthermore, ICU capacity data were unavail-
able for several important countries included in our anal-
yses, such as Algeria, Argentina, Chile, the Dominican 
Republic, Ecuador, Egypt, India, Indonesia, Peru, the 
Philippines, Saudi Arabia and Ukraine.
Statistical analysis
All analyses were performed in Stata V.15.1SE, Stata 
Statistical Software. A 5% threshold of statistical signif-
icance was used for all analyses (p<0.05). Linear 
regressions were performed to assess the univariable 
relationship between each country- level determinant and 
the calculated mean mortality rate for each country. The 
following factors were included in the univariable anal-
yses: the natural logarithm of the population in 2018 
(10 million increase), percentage of population aged 
65 years and over, pollution levels, mean temperature 
(January–May), international arrivals in 2018 (1 million 
increase), population density, prevalent diabetes, prev-
alent neoplasms, median BMI, prevalent hypertension, 
smoking prevalence, hospital beds (per 10 000 popula-
tion), WHO health index, percentage population living 
in urban areas, GDP per capita (PPP), UV radiation 
exposure, mean BCG coverage and the SI. The following 
determinants reaching a p value <0.3 at univariable level 
were then included in a multivariable logistic regression 
model with the natural logarithm of the mean mortality 
rate as outcome: the logarithm of the total population in 
2018, percentage of population aged 65 years and over, 
pollution, mean temperature (January–May), interna-
tional arrivals, population density, prevalent neoplasms, 
prevalent hypertension, the WHO health index, popula-
tion living in urban areas, GDP per capita, UV radiation 
exposure, mean BCG coverage and the SI. Such a deter-
minant selection process was chosen in order to lessen 
the likelihood of excluding factors that may be important 
but would not reach statistical significance due to the 
relatively small sample size of the study.
Given that testing capacity data for 8 (Algeria, Brazil, 
Egypt, France, Germany, the Netherlands, Spain and 
Sweden) of the 37 included countries were not avail-
able, a secondary analysis also including testing capacity 
as a determinant was performed considering only 
the remaining 29 countries. Linear regressions were 
performed to assess the univariable relationship between 
each country- level determinant and the calculated mean 
mortality rate for each country. The following determi-
nants reaching a p value <0.3 at univariable level were 
then included in a multivariable logistic regression model 
with the natural logarithm of the mean mortality rate as 
outcome: the logarithm of the total population in 2018, 
percentage of population aged 65 years and over, interna-
tional arrivals, population density, prevalent neoplasms, 
prevalent hypertension, GDP per capita, UV radiation 
exposure, mean BCG coverage, the SI and testing capacity.
RESULTS
Table 1 and online supplemental file 1 detail the anal-
ysed data for the 37 included countries, including the 
calculated mean mortality rates. The mean mortality 
rates ranged between 0.22 (Chile) and 43.74 (the USA) 
new daily deaths. Only five included countries had a 
high mean mortality rate (>10): the USA (43.74), Spain 
(29.23), the UK (24.05), France (22.13), Italy (18.79) and 
Brazil (13.09).
Table 2 details the results of the linear regression anal-
yses. The following country- level determinants showed 
a statistically significant relationship with log mean 
mortality rate in univariable analyses: natural logarithm of 
population, international arrivals, prevalent neoplasms, 
prevalent hypertension, GDP per capita and BCG vacci-
nation coverage. On multivariable adjustment, interna-
tional arrivals in 2018, as a marker of global connection, 
was significantly associated with an increase in the log 
mean mortality rate (0.033 (95% CI 0.012 to 0.054) per 
1 million increase in international arrivals, p=0.003). This 
translates to an exp(B) of 1.034, equivalent to a 3.4% 
increase in the mean mortality rate for every 1 million 
increase in the number of international arrivals in 2018. 
Furthermore, the mean BCG vaccination coverage was 
associated with a decrease in log mean mortality rate 
(−0.018 (95% CI −0.034 to –0.002) per 1% increase in 
BCG vaccination coverage, p=0.031). This translates to an 
exp(B) of 0.982, equivalent to a 1.8% decrease in mean 
mortality rate for every 1% increase in BCG vaccination 
coverage. Figures 2 and 3 detail the relationship between 
the country- level log mean mortality rate (predicted and 
observed) and each country- level determinant included 
in the multivariable regression model.
Table 3 details the results of the secondary linear 
regression analyses, including only countries having 
reported COVID-19 testing data up to 8 June 2020. The 
following country- level determinants showed a statis-
tically significant relationship with log mean mortality 
rate at univariable level: natural logarithm of popula-
tion, international arrivals, prevalent neoplasms, preva-
lent hypertension, BCG vaccination coverage and total 
COVID-19 tests per 1000 population performed until 8 
June 2020. On multivariable adjustment, the statistically 
significant determinants of log mean mortality rate were: 
international arrivals in 2018 (0.036 (95% CI 0.008 to 
0.063) per 1 million increase in international arrivals, 
p=0.013), prevalent hypertension (−0.129 (95% CI −0.246 
to –0.012) per 1% increase in country- level hypertension 
prevalence, p=0.032) and testing capacity (0.018 (95% CI 
 on F









pen: first published as 10.1136/bm





5Pana TA, et al. BMJ Open 2021;11:e042034. doi:10.1136/bmjopen-2020-042034
Open access
0.001 to 0.034) for 1 per 1000 population increase in the 




In this ecological study including data from 37 coun-
tries that were most severely affected by COVID-19 in 
the first wave of current global pandemic, we assessed 
19 country- level socioeconomic, environmental, health 
and healthcare system and globalisation parameters as 
potential determinants of the death rates associated with 
COVID-19. In the multivariable linear regression model, 
the main determinant that reached statistical significance 
was international arrivals, a proxy of global connection: a 
1 million increase in the number of international arrivals 
in 2018 was associated with a 3.4% increase in the mean 
daily increase in COVID-19 deaths during the ascending 
phase of the first wave of the pandemic. Furthermore, 
country- level BCG vaccination coverage was associated 
with decreases in the COVID-19 mean mortality rate 
during the first wave of the pandemic. Finally, in our 
secondary analyses including only country with avail-
able testing capacity data, the total number of COVID-19 
tests performed per 1000 population until 8 June 2020 
was also associated with increases in the COVID-19 mean 
mortality rate.
Comparison with previous literature
A previous ecological study analysed the country- level 
determinants of the COVID-19 case fatality rate including 
65 countries.3 This study found that on adjustment for 
epidemic age, health expenditure and world region, 
the case fatality rate was significantly associated with 
increasing cumulative number of COVID-19 cases and 
decreasing testing intensity.3 Nevertheless, no other 
country- level determinants were included in this study.
Further comparisons can be made with data from 
previous pandemics. A negative association has been 
reported between health expenditure and death rates 
from the 2009 influenza pandemic in 30 European coun-
tries.24 Associations have also been reported between 
airline travel and spread of the H1N1 influenza virus 
infection.36
Table 1 Observed mean mortality rate during the 
ascending phase of the first wave of the COVID-19 
pandemic and number of international arrivals in 2018 
(millions) for each country included in the analyses
Country
Mean mortality rate 
(daily increase in 





High mean mortality rate
  USA 43.74 79.75
  Spain 29.23 82.77
  UK 24.05 36.32
  France 22.13 89.32
  Italy 18.79 61.57
  Brazil 13.09 6.62
Medium mean mortality rate
  Belgium 7.86 9.12
  Mexico 7.15 41.31
  Germany 6.58 38.88
  The Netherlands 5.4 18.78
  Turkey 3.48 45.77
  India 3.48 17.42
  Canada 3.27 21.13
  Sweden 2.59 7.44
  Russian 
Federation
2.52 24.55
  Peru 2.05 4.42
Low mean mortality rate
  Switzerland 1.6 10.36
  Ireland 1.58 10.93
  Portugal 1.03 16.19
  Algeria 0.88 2.66
  South Africa 0.84 10.47
  Ecuador 0.81 2.54
  Poland 0.79 19.62
  Indonesia 0.72 15.81
  Austria 0.7 30.82
  Romania 0.6 11.72
  Egypt 0.5 11.2
  Japan 0.48 31.19
  Saudi Arabia 0.48 15.33
  Philippines 0.46 7.17
  Colombia 0.42 3.9
  Hungary 0.38 17.55
  Ukraine 0.31 14.1
  Dominican 
Republic
0.28 6.57
  Finland 0.26 3.22
  Argentina 0.25 6.94
Continued
Country
Mean mortality rate 
(daily increase in 





  Chile 0.22 5.72
Countries were categorised in three groups: high mean mortality 
rate group (>20 additional daily deaths), medium mean mortality 
rate group (2–20 additional daily deaths) and low mean mortality 
rate group (<2 additional daily deaths).
Table 1 Continued
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Comorbidities may account for mortality rate differ-
ences between countries. A study among laboratory- 
confirmed cases of COVID-19 in China showed that 
patients with any comorbidity, including diabetes, malig-
nancy and hypertension, had poorer clinical outcomes 
than those without.5 We thus accounted for country- level 
data on a selection of key comorbidities that included 
prevalent diabetes mellitus, neoplasms and hypertension. 
BMI ≥40 kg/m2 has been identified as an independent 
risk factor for severe COVID-19 illness.7 Finally, a recent 
systematic review on five studies from China showed that 
smoking is likely associated with negative outcomes and 
progression of COVID-19.6
Interpretation of findings
In our multivariate model, the main significant determi-
nant of mortality was international arrivals. Travel restric-
tions and their effectiveness in containing respiratory 
virus pandemics remains a contentious subject. In 2007, 
the WHO published a protocol on ‘rapid operations to 
contain the initial emergence of pandemic influenza’, 
which included recommendations on travel restrictions.37 
However, subsequent guidance advises such restrictions 
are not recommended once a virus has spread signifi-
cantly.38 A recent systematic review of 23 studies that 
demonstrated limited impact of travel restrictions in the 
containment of influenza: internal travel restrictions 
delayed pandemic peak by approximately 1.5 weeks, 
while 90% air travel restriction delayed the spread of 
pandemics by approximately 3–4 weeks but only reduced 
attack rates by less than 0.02%.39 However, another 
systematic review of combination strategies for pandemic 
influenza response showed that combination strategies 
including travel restrictions increased the effectiveness of 
individual policies.40
The WHO recommendations for pandemic prepared-
ness and resilience suggest that points of entry into the 
country should be monitored by focusing on surveil-
lance and risk communication to travellers but falls short 
of closing down international travel.41 Interestingly, 
during the COVID-19 pandemic, some countries such 




Coefficient (95% CI) P value Coefficient (95% CI) P value
Natural logarithm of population (10 million 
increase) (2018)
0.432 (0.050 to 0.814) 0.033 0.393 (−0.087 to 0.873) 0.103
% population aged 65 years and older 0.065 (−0.010 to 0.139) 0.097 −0.020 (−0.143 to 0.103) 0.741
Pollution levels −0.017 (−0.044 to 0.011) 0.247 −0.005 (−0.031 to 0.020) 0.659
Mean emperature (January–May) (2010–2016) −0.031 (−0.078 to 0.017) 0.218 0.052 (−0.025 to 0.128) 0.175
International arrivals (1 million increase)(2018) 0.049 (0.033 to 0.064) <0.001 0.033 (0.012 to 0.054) 0.003
Population density −0.002 (−0.006 to 0.002) 0.268 −0.001 (−0.004 to 0.002) 0.560
Diabetes prevalence (% of population ages 20–79 
years) (2019)
−0.0031 (−0.189 to 0.126) 0.700 – –
Prevalence – neoplasms – sex: Both – age: age 
standardised (%)(2017)
0.614 (0.209 to 1.019) 0.005 −0.404 (−1.079 to 0.271) 0.227
Median BMI 0.010 (−0.297 to 0.318) 0.947 – –
Prevalent hypertension (%) (2015) −0.150 (−0.254 to −0.045) 0.008 −0.107 (−0.249 to 0.035) 0.132
Smoking prevalence, 2016 total (ages 15+ years) 0.002 (−0.058 to 0.062) 0.952 – –
Hospital beds (per 10 000 population) −0.004 (−0.022 to 0.014) 0.632 – –
WHO health index (2000) 2.259 (−0.920 to 5.439) 0.173 −2.616 (−6.157 to 0.925) 0.140
Population living in urban areas (%) 0.023 (−0.011 to 0.580) 0.193 0.010 (−0.019 to 0.039) 0.468
GDP per capita, PPP ($1000 increase) (2018) 0.280 (0.037 to 0.524) 0.030 0.154 (−0.174 to 0.482) 0.340
Country- level average daily ambient ultraviolet 
radiation level – 2004
−0.000 (−0.001 to 0.000) 0.133 −0.001 (−0.001 to 0.000) 0.109
Mean % of BCG vaccination coverage among 
1- year- old children (1980–2019)
−0.027 (−0.037 to −0.016) <0.001 −0.018 (−0.034 to −0.002) 0.031
Mean daily stringency index −0.036 (−0.072 to 0.001) 0.057 0.004 (−0.028 to 0.037) 0.790
R2 for multivariable linear regression=0.8031.
The determinants achieving a 30% statistical significance level in univariable analyses (p<0.3) were included in the multivariable model.
Statistically significant results (P <0.05) are displayed in bold.
BMI, body mass index; GDP, gross domestic product; PPP, purchasing power parity.
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as Thailand have adopted aggressive international travel 
screening and isolation policies, which may have led to 
lower infection rates.42 Our study suggests that travel 
restrictions have the potential to influence the impact 
of the COVID-19 pandemic and should be considered 
as part of a structured and rapidly instigated pandemic 
preparedness plan.
Our multivariable model also suggests an inverse rela-
tionship between BCG vaccination coverage and the 
mean mortality rate, in which increasing BCG vaccination 
coverage was associated with decreased mean mortality 
rate. The relationship between BCG vaccination and 
the evolution of the COVID-19 transmission and disease 
severity remains controversial.43 44 While the BCG vaccine 
has been postulated to exhibit non- specific immunomodu-
latory properties, which may reduce SARS- CoV-2 viraemia 
after exposure,43 current epidemiological evidence is 
derived from ecological studies45 and needs to be inter-
preted in the light of the inherent limitations of this 
study design. Further ongoing studies (NCT0432720646 
and NCT0432844147) may provide more robust evidence 
regarding the association between BCG vaccination and 
COVID-19.
Our analyses also revealed a few surprising findings: 
the intensity of COVID-19 testing was apparently asso-
ciated with mean mortality rate increases, while the 
country- level prevalence of hypertension was apparently 
associated with mean mortality rate decreases. These 
findings appear to be contradictory to previous evidence 
suggesting that testing intensity may be associated with 
decreased COVID-19 mortality,48 while hypertension 
was clearly associated with increased mortality.49 These 
surprising findings need to be interpreted in the light of 
our ecological study design in which residual confounders 
may influence these associations.
Strengths and limitations
The main strength of this study lies in its use of compa-
rable and relevant outcome data derived from contem-
porary death reporting from countries affected by 
COVID-19. As testing rates for the virus vary across coun-
tries, the incidence or prevalence of the disease cannot 
be compared between countries. While death from the 
disease is a hard outcome, the denominator information 
to calculate death rates make between- country compari-
sons difficult. In addition, the deaths in the community, 
particularly in the elderly living in care homes, often go 
untested, and thus, firm diagnosis remains impossible. 
Therefore, in this study, we have adopted an outcome 
that is comparable in terms of the increase in the rate 
of death, rather than death rates per se. This may better 
represent the spread and seriousness of pandemic in indi-
vidual countries when comparing countries at different 
stages of the pandemic. The country- level parameters 
assessed as potential factors have all been implicated 
at some point to be associated with severity and conse-
quently mortality. We however found that the main deter-
minant was the total number of international arrivals in 
the country (2018 figures), signifying transmission of the 
infection through travel. Although the data were from 
2018, there is no reason to believe that international 
travel figures between countries would be different in 
early 2020. Furthermore, our multivariable model also 
accounts for country- level international travel restrictions 
adopted in response to the spread of COVID-19.
The main limitation of the study stems from the ecolog-
ical study design. Despite the fact that we did not find 
any association between comorbidities such as diabetes 
and cancer and the mean death rates at country level, it is 
possible for an individual with any or all of these comorbid 
conditions to be more susceptible to the infection and 
consequently at increased risk of dying. Only including 
countries that had reported at least 25 deaths reduced 
our sample and consequently the power. Furthermore, 
the reasonably large number of country- level determi-
nants relative to the number of countries means that we 
cannot rule out the potential for overfitting in the multi-
variable model. This may lead to spurious associations 
between determinants and the outcome. Other explana-
tory variables associated with COVID-19 related mortality 
may have been missed, and some of the covariate data 
used in our model predate the COVID-19 outbreak and 
may not be relevant at this time point. Furthermore, as 
new countries are affected by the epidemic, the viru-
lence of the virus and resistance of the human body may 
have changed over time, which was not accounted for 
in our model. It is also possible that the quality of data, 
especially under- reporting of deaths related to between- 
country differences in defining COVID-19 deaths, may 
have been associated with some of the determinants in 
our model as well as our chosen outcome and thus biased 
Figure 2 Predicted (based on the results of the multivariable 
linear regression) and observed country- level mortality rate 
(mean daily increase in deaths until the peak in mortality) as a 
function of the recorded country- level number of international 
arrivals in 2018 (millions). The solid red line represents the 
point estimate of the predicted log daily increase in deaths, 
while the blue- grey area represents the corresponding 95% 
CI. The crosses represent the observed values of the log daily 
increase in deaths.
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our results. Furthermore, the delay between COVID-19 
symptom onset and hospitalisation may be an important 
factor in the overall clinical prognosis of patients with 
severe COVID-19 disease. Nevertheless, given that our 
analyses rely on country- level determinants and in the 
absence of individual patient data, it is impossible to 
ascertain the country- level trends of delay to hospital 
admission. Notwithstanding, some other country- level 
parameters pertaining to the accessibility of healthcare 
included in our analyses such as the number of hospital 
beds per 10 000 population, proportion of population 
living in urban areas as well as the WHO health index 
may account for such differences. Finally, we did not 
include ICU capacity data in our analyses due to a lack of 
a reliable data source centralising this variable. Neverthe-
less, our analyses account for country- level hospital beds 
per 10 000 population as an indicator of health systems’ 
coping capacity with increased pressures related to the 
pandemic.
CONCLUSION
Out of all the country- level parameters assessed, interna-
tional travel was the main determinant of the severity of 
the first global wave of the COVID-19 pandemic. Given 
that many of world middle- income and lower income 
countries are showing signs of continued rise in infec-
tion rates, international travel restrictions applied very 
early in the pandemic course should be considered to 
avoid rapidly increasing infection and death rates glob-
ally. The associations between other determinants, such 
as BCG vaccination coverage, prevalent hypertension and 
Figure 3 Predicted (based on the results of the multivariable linear regression) and observed country- level mortality rate (mean 
daily increase in deaths until the peak in mortality) as a function of each country- level determinant included in the multivariable 
model. The solid red lines represent the point estimates of the predicted log daily increase in deaths, while the blue- grey areas 
represent the corresponding 95% CI. The crosses represent the observed values of the log daily increase in deaths.
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COVID-19 testing capacity, and the outcome were weaker 
and need to be interpreted in the light of our ecological 
study design. Further studies are required to determine 
the relationship between previous BCG vaccination and 
COVID-19 disease progression.
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Coefficient (95% CI) P value Coefficient (95% CI) P value
Natural logarithm of population (10 million increase) 
(2018)
0.419 (0.038 to 0.800) 0.040 0.385 (−0.044 to 0.813) 0.075
% population aged 65 years and older 0.035 (−0.047 to 0.118) 0.407 – –
Pollution levels −0.003 (−0.037 to 0.030) 0.848 – –
Mean temperature (January–May) (2010–2016) −0.032 (−0.081 to 0.017) 0.207 0.026 (−0.052 to 0.104) 0.484
International arrivals (1 million increase) (2018) 0.059 (0.039 to 0.079) <0.001 0.036 (0.008 to 0.063) 0.013
Population density 0.002 (−0.002 to 0.007) 0.270 0.000 (−0.004 to 0.003) 0.822
Diabetes prevalence (% of population ages 20–79 
years) (2019)
0.012 (−0.173 to 0.196) 0.903 – –
Prevalence – neoplasms – sex: both – age: Age- 
standardised (%) (2017)
0.582 (0.177 to 0.987) 0.009 −0.391 (−1.014 to 0.233) 0.203
Median BMI 0.107 (−0.205 to 0.419) 0.507 – –
Prevalent hypertension (%) (2015) −0.140 (−0.240 to −0.039) 0.011 −0.129 (−0.246 to −0.012) 0.032
Smoking prevalence, 2016 total (ages 15+ years) −0.016 (−0.077 to 0.045) 0.610 – –
Hospital beds (per 10 000 population) −0.009 (−0.027 to 0.009) 0.323 – –
WHO health index (2000) 1.247 (−2.180 to 4.675) 0.482 – –
Population living in urban areas (%) 0.007 (−0.030 to 0.044) 0.710 – –
GDP per capita, PPP ($1000 increase) (2018) 0.242 (−0.016 to 0.499) 0.077 −0.045 (−0.325 to 0.235) 0.739
Country- level average daily ambient ultraviolet 
radiation level – 2004
−0.000 (−0.001 to 0.000) 0.283 0.000 (−0.001 to 0.000) 0.310
Mean % of BCG vaccination coverage among 
1- year- old children (1980–2019)
−0.028 (−0.039 to -0.017) <0.001 −0.011 (−0.029 to 0.007) 0.221
Mean daily stringency index −0.033 (−0.074 to 0.008) 0.128 0.013 (−0.021 to 0.048) 0.425
Total COVID-19 tests per 1000 population (up to 8 
June 2020)
0.024 (0.008 to 0.039) 0.007 0.018 (0.001 to 0.034) 0.039
R2 for multivariable linear regression=0.8373.
The determinants achieving a 30% statistical significance level in univariable analyses (p<0.3) were included in the multivariable model.
Statistically significant results (P <0.05) are displayed in bold.
BMI, body mass index; GDP, gross domestic product; PPP, purchasing power parity.
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